Carregant...
Primaquine for preventing relapse in people with Plasmodium vivax malaria treated with chloroquine
BACKGROUND: Plasmodium vivax infections are an important contributor to the malaria burden worldwide. The World Health Organization recommends a 14‐day course of primaquine (0.25 mg/kg/day, giving an adult dose of 15 mg/day) to eradicate the liver stage of the parasite and prevent relapse of the dis...
Guardat en:
| Publicat a: | Cochrane Database Syst Rev |
|---|---|
| Autors principals: | , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
John Wiley & Sons, Ltd
2013
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6532739/ https://ncbi.nlm.nih.gov/pubmed/24163057 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/14651858.CD004389.pub3 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|